Navigation Links
Catabasis Closes $32.4 Million Series B Financing
Date:11/14/2013

CAMBRIDGE, Mass., Nov. 15, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced it has completed a $32.4 million Series B financing round led by new investor Lightstone Ventures. A leading public crossover fund and all current Catabasis investors, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures, also participated in the financing.

"This investment reflects our confidence in Catabasis' pipeline of SMART Linker conjugates as much as our belief in management's ability to successfully advance its clinical candidates," said Jean George, partner of Lightstone Ventures. "Catabasis has achieved a number of important milestones in the past year including positive data from Phase 1 studies of both CAT-2003 and CAT-1004. We look forward to working with the management team as they complete the ongoing Phase 2 trial for CAT-2003 and seek to advance the rest of the pipeline."

Catabasis plans to use proceeds from this financing to support the development of its lead compound, CAT-2003, a modulator of the lipid synthesis pathway, which is currently in a Phase 2 clinical trial in patients with hypertriglyceridemia and in combination with statins in patients with hypercholesterolemia. Catabasis also plans to use the proceeds to support the continued clinical and pre-clinical development of other SMART Linker conjugates in the pipeline.

"We are tremendously excited about the progress we've made with our pipeline thus far, having reported positive Phase 1 data for both CAT-2003 and CAT-1004 and having advanced CAT-2003 to Phase 2," said Jill Milne, Ph.D., co-founder and chief executive officer of Catabasis. "This financing enables Catabasis to continue to execute on the promise of its pipeline for dyslipidemias and diseases involving chronic inflammation."  '/>"/>

SOURCE Catabasis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
2. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
3. Catabasis Names Ian Sanderson Chief Financial Officer
4. Independa Closes Convertible Note Funding at $2.35 Million
5. Stereotaxis Closes $18.5 Million Private Placement Financings
6. Boston Scientific Closes Cameron Health Acquisition
7. C8 MediSensors Closes $19 million Preferred Stock Financing
8. Igenica Closes $33 Million in Series C Funding
9. BONESUPPORT Closes Second Tranche of Funding
10. PTC Therapeutics Closes $30 Million Financing
11. Chiasma Closes $38.5 Million Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... DALLAS , April 17, 2015 ... report 2015 Market Research Report on Global and ... This is a professional and the deep ... the report introduces Lysine basic information including definition, ... overview (such as US, Europe ...
(Date:4/17/2015)... R.I , April 17, 2015 CVS ... a conference call on Friday, May 1, 2015, at ... its first quarter financial results. An audio ... through the Investor Relations portion of the CVS Health ... visit http://investors.cvshealth.com . This webcast will be archived ...
(Date:4/17/2015)... SAN DIEGO , April 17, 2015 /PRNewswire/ ... molecular diagnostics, announced today that clinical data presented ... demonstrate that its urine-based Precision Cancer Monitoring ℠ ... detection and monitoring of EGFR T790M ... titled Detection of EGFR T790M Mutation in ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
... The ALS Therapy Development Institute (ALS ... with Neurotune to investigate a potential treatment ... (Photo: http://photos.prnewswire.com/prnh/20120514/DC05793 ) ... health of motor neurons and their connections to muscles ...
... 2012  NxStage® Medical, Inc. (Nasdaq: NXTM ... today announced that former NxStage® System One™ patient ... transplant following four successful years of more frequent ... (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) The ...
Cached Medicine Technology:The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 2The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease 3Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant 2Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant 3
(Date:4/18/2015)... 2015 Carinsurancesavings.biz has released a new ... are cheaper during Spring. , Spring can be ... Drivers should make sure they compare the newest policies ... can learn more about Spring car insurance offers by ... insurance quotes are becoming more and more popular. Many ...
(Date:4/18/2015)... SMITHTOWN, NEW YORK (PRWEB) April 18, 2015 ... Inc. (AMO) are hosting a ‘Strategies for Success’ program ... & Refractive Surgeons meeting in San Diego, where eye ... ‘Distinguished Moderator’ for this invitation-only event. Dr. Martin is ... AMO and Review of Ophthalmology chose Dr. Martin to ...
(Date:4/18/2015)... Patients who undergo radiation for a hematologic ... life, but the disease is likely to differ in ... radiation. Surviving Mesothelioma has just posted the details of ... to read it now. , Scientists from China, ... patients who had both a hematologic cancer (like lymphoma ...
(Date:4/18/2015)... On April 14th, 2015, Symantec released Volume ... say, “exposes a tactical shift by cyberattackers.” With everything from ... in 2014 - almost a million a day - to ... identified and patched by prominent manufacturers – as long as ... in a digital world can be fraught with peril, and ...
(Date:4/18/2015)... 2015 French physician and gastronome Anthelme ... when he uttered, “Tell me what you eat, and ... to cope with stress or sadness has often been ... indicates otherwise. Data collected from their Emotional Eating ... emotional eating, but for different reasons. , Collecting data ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6
... given the same procedure by an average of 4.5 years, ... ,And while younger people tend to live longest of ... life compared with those who have not had liver transplants, ... life expectancy and years of life lost of 2702 people ...
... performed by physicians experienced with the technique//, and pain ... one-year, multi-center cohort study. ,Among the 25 patients ... on a 10-point visual analog scale was 7.3 at ... at 24 weeks, and 0.3 at 52 weeks, according ...
... for treating patients with advanced colorectal cancer has been approved ... other parts of the body.//Panitumamab, which is being marketed as ... size and retard cancer cell growth. ,The approval has ... which has a high mortality rate. Colorectal cancer has been ...
... women after consumption of raw oysters. Further probing revealed that ... ,Agriculture Commissioner Tommy Irvin commenting on the deaths said “The ... and they lost their lives.” In his opinion, raw oysters ... DeKalb Farmers’ Market reiterated that they have always been enabling ...
... Recent studies conducted by Yale School Of Medicine have ... androgens or steroids to enhance muscle mass or for ... in the body can lead to a appalling loss ... steroids was previously proven to cause hyper excitability, volatile ...
... is the most notorious of cancers, going by the United Kingdom ... of three cases happens to be of the breast. , ... increase in cancer. The present record for breast cancer is 36,939 ... cancer is up since 1971 by almost 81%. ...
Cached Medicine News:Health News:Sacroplasty Safe and Effective to Reduce Low Back Pain 2Health News:Sacroplasty Safe and Effective to Reduce Low Back Pain 3Health News:FDA Approves Vectibix for Colorectal Cancer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: